BioCardia, Inc.(BCDA)Earnings, Financials & Key Ratios
BCDA•NASDAQ
$1.09
$5M mkt cap·Price updated May 7, 2026
AboutBioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.Show more
- Revenue$58K-87.8%
- EBITDA-$8M+31.4%
- Net Income-$8M+31.3%
- EPS (Diluted)-2.90+64.6%
- Gross Margin-7463.79%-391.1%
- EBITDA Margin-13679.31%-464.4%
- Operating Margin-13794.83%-465.1%
- Net Margin-13700%-464.8%
- ROE-949.34%-34.9%
- Debt/Equity1.14
BCDA Key Insights
BioCardia, Inc. (BCDA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 20 (bottom 20%)
- ✗Sales declining 39.4% over 5 years
- ✗Shares diluted 94.3% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BCDA Price & Volume
BioCardia, Inc. (BCDA) stock price & volume — 10-year historical chart
Loading chart...
BCDA Growth Metrics
BioCardia, Inc. (BCDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-18.1%
5 Years-39.41%
3 Years-61.48%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.59%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-5542.65%
Return on Capital
10 Years-349.43%
5 Years-562.14%
3 Years-864.6%
Last Year-2046.29%
BCDA Peer Comparison
BioCardia, Inc. (BCDA) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MCRB | 74.36M | 7.72 | 12.06 | -40.89% | -127.3% | 1.88 | ||
 ANIK | 202.89M | 15.14 | -19.92 | -5.91% | -9.52% | -7.74% | 0.17 | |
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ADMA | 2.03B | 8.47 | 14.12 | 19.63% | 32.43% | 38.97% | 0.17 | |
 VCEL | 1.79B | 35.13 | 109.78 | 16.45% | 7.35% | 6.41% | 0.28 | |
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 MDXG | 548.21M | 3.69 | 11.53 | 19.99% | 7.88% | 12.86% | 0.09 | |
 RGEN | 7.13B | 126.43 | 147.01 | 16.36% | 6.73% | 2.46% | 0.33 |
Compare BCDA vs Peers
BioCardia, Inc. (BCDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCDA Income Statement
BioCardia, Inc. (BCDA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 576K | 479K | 625K | 710K | 145K | 1.01M | 1.35M | 477K | 58K | 0 |
| Revenue Growth % | 11.41% | -16.84% | 30.48% | 13.6% | -79.58% | 600% | 33.2% | -64.72% | -87.84% | -100% |
| Cost of Goods Sold | 746K | 690K | 517K | 358K | 4K | 640K | 8.83M | 7.73M | 4.39M | 4.42M |
| COGS % of Revenue | 129.51% | 144.05% | 82.72% | 50.42% | 2.76% | 63.05% | 653.4% | 1619.71% | 7563.79% | - |
| Gross Profit | -170K▲ 0% | -211K▼ 24.1% | 108K▲ 151.2% | 352K▲ 225.9% | 141K▼ 59.9% | 375K▲ 166.0% | -7.48M▼ 2095.2% | -7.25M▲ 3.1% | -4.33M▲ 40.3% | -4.42M▲ 0% |
| Gross Margin % | -29.51% | -44.05% | 17.28% | 49.58% | 97.24% | 36.95% | -553.4% | -1519.71% | -7463.79% | - |
| Gross Profit Growth % | 89.85% | -24.12% | 151.18% | 225.93% | -59.94% | 165.96% | -2095.2% | 3.11% | 40.28% | - |
| Operating Expenses | 7.44M | 12.19M | 14.21M | 14.56M | 15.67M | 13.01M | 4.42M | 4.39M | 3.67M | 4.17M |
| OpEx % of Revenue | 1291.32% | 2545.72% | 2273.6% | 2051.41% | 10806.9% | 1281.28% | 326.85% | 921.38% | 6331.03% | - |
| Selling, General & Admin | 4.11M | 6.39M | 5.76M | 6M | 5.86M | 5.09M | 0 | 0 | 0 | 449K |
| SG&A % of Revenue | 713.19% | 1335.07% | 921.12% | 845.49% | 4042.07% | 501.18% | - | - | - | - |
| Research & Development | 3.33M | 5.8M | 8.45M | 8.56M | 9.81M | 8.56M | 8.83M | 7.73M | 4.39M | 5.25M |
| R&D % of Revenue | 578.13% | 1210.65% | 1352.48% | 1205.92% | 6764.83% | 843.15% | 653.4% | 1619.71% | 7563.79% | - |
| Other Operating Expenses | -2K | 2K | -3K | 0 | 0 | -640K | -4.42M | -3.33M | -715K | -1.53M |
| Operating Income | -7.61M▲ 0% | -12.4M▼ 63.1% | -14.1M▼ 13.7% | -14.21M▼ 0.8% | -15.53M▼ 9.3% | -12.63M▲ 18.7% | -11.9M▲ 5.8% | -11.64M▲ 2.2% | -8M▲ 31.3% | -8.59M▲ 0% |
| Operating Margin % | -1320.83% | -2589.77% | -2256.32% | -2001.83% | -10709.66% | -1244.34% | -880.25% | -2441.09% | -13794.83% | - |
| Operating Income Growth % | -2484.95% | -63.05% | -13.68% | -0.79% | -9.26% | 18.67% | 5.77% | 2.16% | 31.29% | - |
| EBITDA | -7.57M | -12.33M | -14.01M | -13.66M | -14.96M | -12.57M | -11.82M | -11.56M | -7.93M | -8.45M |
| EBITDA Margin % | -1314.06% | -2573.49% | -2242.24% | -1924.23% | -10319.31% | -1238.42% | -874.19% | -2423.48% | -13679.31% | - |
| EBITDA Growth % | -2168.03% | -62.86% | -13.69% | 2.51% | -9.52% | 15.99% | 5.97% | 2.19% | 31.37% | -11.14% |
| D&A (Non-Cash Add-back) | 39K | 78K | 88K | 551K | 566K | 60K | 82K | 84K | 67K | 139K |
| EBIT | -8.57M | -12.31M | -13.99M | -14.6M | -15M | -12.63M | -11.9M | -11.64M | -8M | -8.58M |
| Net Interest Income | -1.74M | 95K | 118K | -25K | 18K | 9K | -6K | 0 | 0 | 0 |
| Interest Income | 0 | 95K | 118K | 87K | 21K | 9K | 0 | 0 | 0 | 0 |
| Interest Expense | 1.74M | 0 | 0 | 112K | 3K | 0 | 6K | 0 | 0 | 0 |
| Other Income/Expense | -2.7M | 97K | 115K | -496K | 525K | 7K | -6K | 73K | 55K | 46K |
| Pretax Income | -10.31M▲ 0% | -12.31M▼ 19.4% | -13.99M▼ 13.6% | -14.71M▼ 5.2% | -15M▼ 2.0% | -12.62M▲ 15.9% | -11.91M▲ 5.7% | -11.57M▲ 2.8% | -7.95M▲ 31.3% | -8.54M▲ 0% |
| Pretax Margin % | -1789.93% | -2569.52% | -2237.92% | -2071.69% | -10347.59% | -1243.65% | -880.7% | -2425.79% | -13700% | - |
| Income Tax | 0 | 0 | -115K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0.82% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.31M▲ 0% | -12.31M▼ 19.4% | -13.99M▼ 13.6% | -14.71M▼ 5.2% | -15M▼ 2.0% | -12.62M▲ 15.9% | -11.91M▲ 5.7% | -11.57M▲ 2.8% | -7.95M▲ 31.3% | -8.54M▲ 0% |
| Net Margin % | -1789.93% | -2569.52% | -2237.92% | -2071.69% | -10347.59% | -1243.45% | -880.7% | -2425.79% | -13700% | - |
| Net Income Growth % | -3301.86% | -19.38% | -13.64% | -5.16% | -2.01% | 15.88% | 5.66% | 2.82% | 31.33% | -10.59% |
| Net Income (Continuing) | -10.31M | -12.31M | -13.99M | -14.71M | -15M | -12.62M | -11.91M | -11.57M | -7.95M | -8.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -166.33▲ 0% | -43.50▲ 73.8% | -48.80▼ 12.2% | -39.15▲ 19.8% | -22.20▲ 43.3% | -11.19▲ 49.6% | -10.05▲ 10.2% | -8.19▲ 18.5% | -2.90▲ 64.6% | -1360.34▲ 0% |
| EPS Growth % | -697.02% | 73.85% | -12.18% | 19.77% | 43.3% | 49.59% | 10.19% | 18.51% | 64.59% | -5542.65% |
| EPS (Basic) | -166.33 | -43.50 | -48.80 | -39.15 | -22.20 | -11.19 | -10.05 | -8.19 | -2.90 | - |
| Diluted Shares Outstanding | 61.99K | 282.67K | 284.28K | 376.29K | 674.58K | 1.13M | 1.18M | 1.41M | 2.74M | 6.28K |
| Basic Shares Outstanding | 61.99K | 282.67K | 284.28K | 376.29K | 674.58K | 1.13M | 1.18M | 1.41M | 2.74M | 6.28K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BCDA Balance Sheet
BioCardia, Inc. (BCDA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 21.92M | 13.31M | 6.22M | 6.38M | 22.66M | 13.48M | 7.86M | 1.46M | 2.62M | 5.37M |
| Cash & Short-Term Investments | 21.35M | 12.69M | 5.36M | 5.58M | 21.41M | 12.87M | 7.36M | 1.1M | 2.37M | 5.29M |
| Cash Only | 21.35M | 12.69M | 5.36M | 5.58M | 21.41M | 12.87M | 7.36M | 1.1M | 2.37M | 5.29M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 74K | 95K | 274K | 147K | 232K | 147K | 201K | 63K | 0 | 0 |
| Days Sales Outstanding | 46.89 | 72.39 | 160.02 | 75.57 | 584 | 52.86 | 54.26 | 48.21 | - | - |
| Inventory | 135K | 191K | 141K | 4K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 66.05 | 101.04 | 99.55 | 4.08 | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 618K | 0 | 300K | 295K | 251K | 78K |
| Total Non-Current Assets | 165K | 223K | 199K | 1.3M | 766K | 2.24M | 1.93M | 1.53M | 1.1M | 783K |
| Property, Plant & Equipment | 111K | 169K | 145K | 1.25M | 712K | 2.06M | 1.76M | 1.36M | 931K | 612K |
| Fixed Asset Turnover | 5.19x | 2.83x | 4.31x | 0.57x | 0.20x | 0.49x | 0.77x | 0.35x | 0.06x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 54K | 54K | 54K | 54K | 54K | 172K | 171K | 171K | 171K | 684K |
| Total Assets | 22.08M▲ 0% | 13.54M▼ 38.7% | 6.42M▼ 52.6% | 7.68M▲ 19.7% | 23.42M▲ 205.1% | 15.72M▼ 32.9% | 9.79M▼ 37.7% | 2.99M▼ 69.5% | 3.72M▲ 24.7% | 6.15M▲ 0% |
| Asset Turnover | 0.03x | 0.04x | 0.10x | 0.09x | 0.01x | 0.06x | 0.14x | 0.16x | 0.02x | 0.00x |
| Asset Growth % | 59.14% | -38.69% | -52.6% | 19.65% | 205.08% | -32.9% | -37.7% | -69.5% | 24.67% | -24.09% |
| Total Current Liabilities | 1.44M | 2.33M | 2.55M | 4M | 4.25M | 3.71M | 3.58M | 3.61M | 2.32M | 3.31M |
| Accounts Payable | 525K | 902K | 1.02M | 914K | 746K | 507K | 683K | 890K | 385K | 1.08M |
| Days Payables Outstanding | 256.87 | 477.14 | 720.12 | 931.87 | 68.07K | 289.15 | 28.22 | 42.05 | 32.03 | 72.59 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 427K |
| Deferred Revenue (Current) | 137K | 891K | 757K | 0 | 0 | 1.53M | 965K | 561K | 532K | 1.59M |
| Other Current Liabilities | 0 | 724K | 480K | 732K | 1.39M | 0 | 0 | 0 | 378K | 1.8M |
| Current Ratio | 15.18x | 5.71x | 2.44x | 1.59x | 5.33x | 3.63x | 2.19x | 0.40x | 1.13x | 1.13x |
| Quick Ratio | 15.08x | 5.63x | 2.39x | 1.59x | 5.33x | 3.63x | 2.19x | 0.40x | 1.13x | 1.13x |
| Cash Conversion Cycle | -143.93 | -303.72 | -460.55 | -852.22 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 56K | 81K | 77K | 1.3M | 0 | 1.63M | 1.32M | 982K | 566K | 211K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 211K |
| Capital Lease Obligations | 0 | 0 | 0 | 614K | 0 | 1.63M | 1.32M | 982K | 566K | 1.35M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 56K | 81K | 77K | 691K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.5M | 2.41M | 2.63M | 5.31M | 4.25M | 5.34M | 4.9M | 4.59M | 2.89M | 3.52M |
| Total Debt | 0 | 0 | 0 | 1.14M | 614K | 1.87M | 1.63M | 1.31M | 951K | 638K |
| Net Debt | -21.35M | -12.69M | -5.36M | -4.44M | -20.79M | -11M | -5.73M | 212K | -1.42M | -4.65M |
| Debt / Equity | - | - | - | 0.48x | 0.03x | 0.18x | 0.33x | - | 1.14x | 1.14x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.08x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.55x |
| Interest Coverage | -4.38x | - | - | -126.90x | -5176.33x | - | -1983.50x | - | - | - |
| Total Equity | 20.58M▲ 0% | 11.13M▼ 45.9% | 3.79M▼ 65.9% | 2.37M▼ 37.5% | 19.18M▲ 709.1% | 10.38M▼ 45.9% | 4.89M▼ 52.8% | -1.6M▼ 132.8% | 837K▲ 152.2% | 2.63M▲ 0% |
| Equity Growth % | 48.44% | -45.95% | -65.91% | -37.5% | 709.11% | -45.9% | -52.85% | -132.77% | 152.21% | 184.65% |
| Book Value per Share | 332.04 | 39.36 | 13.34 | 6.30 | 28.43 | 9.20 | 4.14 | -1.14 | 0.31 | 418.46 |
| Total Shareholders' Equity | 20.58M | 11.13M | 3.79M | 2.37M | 19.18M | 10.38M | 4.89M | -1.6M | 837K | 2.63M |
| Common Stock | 458K | 38K | 43K | 7K | 16K | 17K | 20K | 2K | 5K | 11K |
| Retained Earnings | -60.14M | -72.45M | -86.36M | -101.07M | -116.07M | -128.7M | -140.6M | -152.18M | -160.12M | -166.37M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -771K | -758K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCDA Cash Flow Statement
BioCardia, Inc. (BCDA) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.52M | -8.67M | -11.07M | -9.45M | -12.36M | -10.37M | -10.56M | -9.97M | -8.03M | -8.03M |
| Operating CF Margin % | -958.68% | -1810.23% | -1771.04% | -1330.28% | -8522.07% | -1021.28% | -781.14% | -2090.99% | -13837.93% | - |
| Operating CF Growth % | -1768.28% | -57.03% | -27.66% | 14.67% | -30.83% | 16.11% | -1.88% | 5.56% | 19.53% | -34.48% |
| Net Income | -10.31M | -12.31M | -13.99M | -14.71M | -15M | -12.62M | -11.91M | -11.57M | -7.95M | -8.54M |
| Depreciation & Amortization | 39K | 78K | 88K | 111K | 68K | 60K | 82K | 84K | 67K | 238K |
| Stock-Based Compensation | 942K | 2.71M | 2.77M | 2.72M | 2.95M | 1.66M | 1.18M | 1.03M | 741K | 346K |
| Deferred Taxes | 1.56M | 0 | 0 | 910K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.74M | 2.56M | 2.96M | 112K | -506K | 599K | 295K | 354K | 329K | 367K |
| Working Capital Changes | 510K | 852K | 56K | 1.41M | 133K | -63K | -214K | 129K | -1.22M | 77K |
| Change in Receivables | 33K | -21K | -179K | 127K | -703K | 703K | -54K | 115K | 97K | 10K |
| Change in Inventory | 27K | -56K | 49K | 136K | 4K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -17K | 377K | 119K | 171K | -168K | -239K | 4K | 184K | -316K | 377K |
| Cash from Investing | 18.92M | -136K | -66K | -146K | -32K | -116K | -70K | -12K | -6K | -2K |
| Capital Expenditures | 0 | -136K | -66K | -146K | -32K | -116K | -70K | -12K | -6K | -2K |
| CapEx % of Revenue | - | 28.39% | 10.56% | 20.56% | 22.07% | 11.43% | 5.18% | 2.52% | 10.34% | - |
| Acquisitions | 18.92M | -18.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -96K | 18.92M | -66K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.4M | 144K | 3.8M | 9.82M | 28.21M | 1.95M | 5.12M | 3.73M | 9.3M | 7.87M |
| Debt Issued (Net) | 4.37M | 0 | 0 | 625K | 506K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 2.23M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 22K | 144K | 0 | -1.26M | -2.79M | -54K | -418K | -662K | -1.25M | -24K |
| Net Change in Cash | 17.8M▲ 0% | -8.66M▼ 148.7% | -7.33M▲ 15.4% | 227K▲ 103.1% | 15.82M▲ 6870.0% | -8.54M▼ 153.9% | -5.51M▲ 35.5% | -6.26M▼ 13.6% | 1.27M▲ 120.3% | 357K▲ 0% |
| Free Cash Flow | -5.52M▲ 0% | -8.81M▼ 59.5% | -11.13M▼ 26.4% | -9.59M▲ 13.9% | -12.39M▼ 29.2% | -10.48M▲ 15.4% | -10.63M▼ 1.4% | -9.99M▲ 6.1% | -8.03M▲ 19.6% | -7.51M▲ 0% |
| FCF Margin % | -958.68% | -1838.62% | -1781.6% | -1350.85% | -8544.14% | -1032.71% | -786.32% | -2093.5% | -13848.28% | - |
| FCF Growth % | -2780.58% | -59.49% | -26.43% | 13.87% | -29.17% | 15.39% | -1.42% | 6.07% | 19.57% | -2.8% |
| FCF per Share | -89.08 | -31.16 | -39.17 | -25.49 | -18.37 | -9.29 | -9.00 | -7.07 | -2.93 | -2.93 |
| FCF Conversion (FCF/Net Income) | 0.54x | 0.70x | 0.79x | 0.64x | 0.82x | 0.82x | 0.89x | 0.86x | 1.01x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCDA Key Ratios
BioCardia, Inc. (BCDA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -59.86% | -77.64% | -187.53% | -477.41% | -139.27% | -85.42% | -155.98% | -703.62% | -949.34% | -325.09% |
| Return on Invested Capital (ROIC) | -231.57% | - | - | - | - | - | - | - | - | 405.96% |
| Gross Margin | -29.51% | -44.05% | 17.28% | 49.58% | 97.24% | 36.95% | -553.4% | -1519.71% | -7463.79% | - |
| Net Margin | -1789.93% | -2569.52% | -2237.92% | -2071.69% | -10347.59% | -1243.45% | -880.7% | -2425.79% | -13700% | - |
| Debt / Equity | - | - | - | 0.48x | 0.03x | 0.18x | 0.33x | - | 1.14x | 1.14x |
| Interest Coverage | -4.38x | - | - | -126.90x | -5176.33x | - | -1983.50x | - | - | - |
| FCF Conversion | 0.54x | 0.70x | 0.79x | 0.64x | 0.82x | 0.82x | 0.89x | 0.86x | 1.01x | 0.88x |
| Revenue Growth | 11.41% | -16.84% | 30.48% | 13.6% | -79.58% | 600% | 33.2% | -64.72% | -87.84% | -100% |
BCDA Frequently Asked Questions
BioCardia, Inc. (BCDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioCardia, Inc. (BCDA) reported $0.1M in revenue for fiscal year 2024. This represents a 98% decrease from $3.1M in 1995.
BioCardia, Inc. (BCDA) saw revenue decline by 87.8% over the past year.
BioCardia, Inc. (BCDA) reported a net loss of $8.5M for fiscal year 2024.
Dividend & Returns
BioCardia, Inc. (BCDA) has a return on equity (ROE) of -949.3%. Negative ROE indicates the company is unprofitable.
BioCardia, Inc. (BCDA) had negative free cash flow of $7.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More BCDA
BioCardia, Inc. (BCDA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates